Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject has Parkinson's disease consistent with the UK Brain Bank Criteria and must have bradykinesia with sequence effect. If rest tremor does not exist must have prominent asymmetry of motor function.~2. Subject with disease duration less than 3 years since diagnosis.~3. Subject has a H\&Y stage score of \< 3.~4. Subject has a MMSE score ≥ 26.~Exclusion Criteria:~1. Subject has an atypical parkinsonian syndrome or secondary parkinsonism~2. Subject has previous exposure to levodopa or a dopamine agonist for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 2 months prior to the baseline visit.~3. Subject has previous exposure to a MAO-B inhibitor for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 3 months prior to the baseline visit.~4. Subject who has taken anticholinergic drugs for PD or amantadine for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 1 month prior to the baseline visit.~5. Subject has moderate (Child-Pugh categorization B, score 7-9) or severe (Child-Pugh categorization C, score 10-15) hepatic impairment.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- P2B001 0.6/0.75 mg (Type: EXPERIMENTAL): Fixed dose combination once daily capsule of pramipexole 0.6mg and rasagiline 0.75mg, + matching placebo tablet
- rasagiline 0.75mg (Type: EXPERIMENTAL): Rasagiline 0.75mg Once daily capsule, component of P2B001, + matching placebo tablet
- Pramipexole 0.6mg (Type: EXPERIMENTAL): Pramipexole 0.6mg once daily capsule, component of P2B001 + matching placebo tablet
- Pramipexole Extended Release (Type: ACTIVE_COMPARATOR): Marketed pramipexole ER tablet titrated to optimal dose of 1.5, 3.0 or 4.5mg + matching placebo capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).